ClinicalTrials.gg
CompletedNCT07518771Updated Apr 9, 2026

PA-001 Ph.1 Study in Healthy and Elderly Subjects

A Phase 1 interventional study of PA-001 in COVID - 19, sponsored by PeptiDream Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by PeptiDream Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.
  • Registered 1 year 7 months after the study started (first participant enrolled Jul 2024, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
841st of 1,321
47 · median 91
Started
2024
with 73 others
Phase 1
178 of 1,859
10 open now
Registered
1,840th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 841st largest by enrollment of the 1,321 interventional ones that give a count, is one of 74 that started in 2024, is one of 178 in phase 1, and was the 1,840th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts. The principal aim of this study was to obtain safety and tolerability data when PA-001 is administered IV as single and multiple doses to healthy subjects. This information, together with the PK data, will help establish the doses and dosing regimen suitable for future studies in patients. The study also investigated the effects of age on the PK of PA-001 prior to patient studies.

03

Conditions studied

  • COVID - 19

Keywords

  • COVID-19
  • SARS-CoV-2 spike protein
  • S2 region of the SARS-CoV-2 spike protein
  • Peptide
  • Spike protein inhibitor
  • coronavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Groups of healthy subjects: Males or females, of any race, between 18 and 65 years of age, inclusive.
  • Group(s) of elderly subjects: Males or females, of any race, > 65 years of age.
  • between 18.0 and 32.0 kg/m2, inclusive.
  • In good health, or have stable, chronic, non life threatening medical conditions, determined by no findings
  • Females will not be pregnant or lactating, and females of and males will agree to use .
  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder that, in the opinion of the investigator (or designee), could impact subject safety or the objectives of the study.
  • Have signs and symptoms of any other liver disease, except nonalcoholic fatty liver disease, or any of the following, as determined from clinical laboratory evaluations:
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
  • Positive hepatitis panel or positive test.
  • Positive SARS-CoV-2 test at screening or check in.
  • Have signs which shows something was not right in the or history of additional risk factors for torsades de pointes.
  • Administration of a COVID 19 vaccine in the past 30 days prior to dosing.
  • Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half lives of that drug prior to dosing, whichever is longer.
  • Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    SAD

    Single-dose, sequential-group of PA-001

    Drug: PA-001

  • Experimental
    MAD

    Multiple-dose, sequential-group of PA-001

    Drug: PA-001

Interventions

  • DrugPA-001

    PA-001 or Placebo was infused via IV in accordance with a randomized schedule, after a fast of at least 10 hours

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events after single and multiple IV dosed of PA-001 in healthy subjects

    An adverse event (AE) was any untoward medical occurrence in a subject, temporally associated with the use of study intervention. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect and resulted in an important medical events. TEAEs were defined as events that occurred after start of treatment.

    Time frame: For approx. 8 weeks

  2. Incidence of laboratory abnormalities (hematology, clinical chemistry and urinalysis test)

    Clinical hematology parameters included: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, mean cell hemoglobin (MCH), MCH concentration and mean cell volume. Chemistry parameters included: blood urea nitrogen, creatinine, estimated glomerular filtration rate, glucose, calcium, sodium, potassium, chloride, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, bicarbonate, gamma-glutamyl transferase, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, B-type natriuretic peptide, highly sensitive troponin T and lactate dehydrogenase. Urinalysis parameters included: potential of hydrogen (pH), glucose, protein, blood, ketones, nitrite, leukocyte esterase, bilirubin, color and appearance, specific gravity.

    Time frame: For approx. 8 weeks

  3. 12-lead electrocardiogram parameters

    A 12-lead ECG was performed. Clinically meaningful findings in ECG assessments were based on the investigator's judgment

    Time frame: For approx. 8 weeks

Secondary outcomes

  1. AUCinf of PA-001 in plasma following single and multiple IV dose

    AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve

    Time frame: SAD: predose to 48 hours after start of infusion, MAD: predose to 48 hours after start of the last infusion

  2. AUClast of PA-001 in plasma following single and multiple IV dose

    AUClast was calculated as area under the concentration time curve from time 0 to the time of the last quantifiable concentration

    Time frame: SAD: predose to 48 hours after start of infusion, MAD: predose to 48 hours after start of the last infusion

  3. Cmax of PA-001 in plasma following a single and multiple IV dose

    Cmax was maximum observed concentration. Cmax was observed directly from data

    Time frame: SAD: predose to 48 hours after start of infusion, MAD: predose to 48 hours after start of the last infusion

  4. T1/2 of PA-001 in plasma following single and multiple IV dose

    T1/2 was terminal elimination half life

    Time frame: SAD: predose to 48 hours after start of infusion, MAD: predose to 48 hours after start of the last infusion

  5. Percent Urinary Recovery of PA-001 following single IV dose

    Percentage of the dose administered recovered over the time interval, 0 hour to the end of collection

    Time frame: SAD only, predose to 48 hours after start of infusion

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc.
    Dallas, Texas 75230, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jun 2025, 10 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 10 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 9, 2026
StartActual
Jul 30, 2024
Primary completionActual
Jun 2, 2025
CompletionActual
Jun 2, 2025
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07518771
Lead sponsor
PeptiDream Inc.
Collaborators
PeptiAID Inc.
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Jul 30, 2024
Primary completion
Jun 2, 2025
Completion
Jun 2, 2025
Last update
Apr 9, 2026

Study contacts

Masato Murakami, MD
study director · PeptiAID Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion